Company Description
BillionToOne is transforming healthcare by redefining molecular diagnostics.
Our revolutionary single molecule NGS (smNGS) platform achieves what was once thought impossible – detecting and precisely quantifying genetic targets with single-molecule sensitivity.
Our superior technology platform has enabled us to build category-defining prenatal and oncology products.
Our products reveal actionable insights from a simple blood draw that are fundamentally changing how diseases are diagnosed and treated, leading to a paradigm shift in personalized medicine.
We believe our novel smNGS platform technologies combined with our AI-enhanced integrated workflow, allows us to push the technology frontier forward and deliver on the full promise of non-invasive liquid biopsy.
| Country | United States |
| Founded | 2016 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 620 |
| CEO | Oguzhan Atay |
Contact Details
Address: 1035 O’Brien Drive Menlo Park, CA 94025 United States | |
| Phone | (650) 460-2551 |
| Website | billiontoone.com |
Stock Details
| Ticker Symbol | BLLN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0002070849 |
| Employer ID | 81-1082020 |
| SIC Code | 8071 |
Key Executives
| Name | Position |
|---|---|
| Oguzhan Atay, PhD | Chief Executive Officer and Chair of the Board |
| David Tsao, PhD | President, Chief Technology Officer and Director |
| Ross Taylor | Chief Financial Officer |
| Shan Riku Sakakibara | Chief Product Officer |
| Thomas Lynch | General Counsel, Chief Compliance Officer and Secretary |
| Nancy Johnson | Senior Vice President of Sales and Commercial Operations |
| John ten Bosch, PhD | Senior Vice President of Laboratory Operations |
| John Lister | Chief Administrative Officer |
| Thomas Bremner | Director |
| Firat Ileri | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 7, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Sep 17, 2025 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Aug 11, 2025 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Jun 20, 2025 | DRS | [Cover] Draft Registration Statement |